Trading Signals: VBIV Stock Price Prediction and Forecast (Thu. May. 4, 2006 - Fri. Jul. 24, 2020)(VBI Vaccines Inc)
| VBIV latest price $5.4650 (-6.1%) ($5.3000 - $5.8000) on Thu. Jul. 23, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.13% (three month average) | RSI | 82 | Latest Price | $5.4650(-6.1%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | VBIV advances 1.6% a day on average for past five trading days. | Weekly Trend | VBIV advances 26.7% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Normal for small cap. | Correlated ETFs | Broad market will support VBIV advance at 0% a week (0% probability) ACES(58%) UNG(14%) SIL(4%) XBI(54%) VWO(18%) | Factors Impacting VBIV price | VBIV will decline at least -4.065% in a week (0% probabilities). GDX(-45%) GDXJ(-12%) EEM(27%) IBB(45%) ARKK(63%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -4.065% (StdDev 8.13%) | Hourly BBV | 0.6 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $5.77(-5.29%) | 10 Day Moving Average | $5.13(6.53%) | 20 Day Moving Average | $4.27(27.99%) | To recent high | -11.3% | To recent low | 9.2% | Market Cap | $1.26b | | | | VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.VBI's COVID-19 vaccine candidate, VBI-2901, is noteworthy because it could potentially also confer immunity to other coronaviruses which cause diseases like MERS (Middle Eastern Respiratory Syndrome). More importantly, VBI appears to be facing a bottleneck either in its preclinical research or its vaccine manufacturing capabilities. VBI doesn't expect to have the necessary clinical study materials assembled for its COVID-19 vaccine trial before the fourth quarter, meaning that it's roughly a quarter behind Vaxart in the development process. |